pcn poster

Posters

Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study

Background: Antipsychotic treatment of schizophrenia is often associated with increased rates of metabolic syndrome (MetSy), as defined by criteria for waist circumference, triglycerides,...

Suresh Durgam , MD;

Christoph U. Correll , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

John Edwards , MD, MBA;

Richard Chen , PhD;

10/08/2020

A Combination of Olanzapine and Samidorphan in Adults With Schizophrenia and Bipolar I Disorder: Overview of Clinical Data

Objectives: Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is hindered by significant weight gain. A combination of olanzapine and samidorphan...

Mark Todtenkopf , PhD;

Lauren DiPetrillo , PhD;

Hannah Cummings , PhD;

Leslie Citrome , MD;

Adam Simmons , MPH;

David McDonnell , MD;

Ying Jiang , PhD;

Lei Sun , PhD;

Christine Graham , PhD;

Bernard Silverman , MD;

10/08/2020

A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Anti-psychotic Medications

Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...

Kruti Joshi , MPH, MD;

Edward S. Kim , MD, FACP, MBA;

Christoph U. Correll , MD;

Charmi Patel , BS , RN, BSN, MPH;

Amber Martin , BS;

Rebecca Goulding , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Emma Schiller , BA;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Poster

Add-on Pimavanserin Improves Insomnia, Sleepiness in MDD Study

09/13/2020

A secondary analysis of a study investigating adjunctive pimavanserin for the treatment of patients with major depressive disorder found that it significantly improved insomnia and sleepiness, researchers reported at Psych Congress 2020.

A secondary analysis of a study...

09/13/2020

Psych Congress Network

A Phase 3, Multicenter Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Olanzapine/Samidorphan in Patients With Schizophrenia

Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM), is in development for the treatment of schizophrenia and is intended to provide the antipsychotic efficacy of...

Christina Arevalo , MS;

Sergey Yagoda , PhD, MD;

Christine Graham , PhD;

Yangsong Cheng , PhD;

Adam Simmons , MPH;

David McDonnell , MD;

11/22/2019

Lumateperone in the Treatment of Schizophrenia: Efficacy in Demographic and Clinical Subgroups

Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...

Sharon Mates , PhD;

Kimberly Vanover , PhD;

Ian D'Souza , PhD;

Roger McIntyre , MD, FRCPC;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

11/22/2019

Defining “Adequately Treated”: Characteristics of Patients With Schizophrenia Successfully Transitioned From Paliperidone Palmitate Once Monthly to Paliperidone Palmitate Once-Every-3-Months

Objective: To identify patient characteristics associated with successful transition to once-every-3-months paliperidone palmitate (PP3M).

Edward S. Kim , MD, FACP, MBA;

Amy O'Donnell , MD, JD, BS;

Sanjai Rao , MD;

Ibrahim Turkoz , PhD;

Srihari Gopal , MD;

11/22/2019

Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries

Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...

Charmi Patel , BS , RN, BSN, MPH;

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Patrick Lefebvre , MA;

Aurélie Côté-Sergent , MSc;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

11/22/2019

Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin

Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY...

Srdjan Stankovic , MD, MSPH;

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Bryan Dirks , MD, MSc, MBA;

Manish Jha ;

Marlene Freeman , MD;

George Papakostas , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

11/22/2019

Impact of Individual and Class of Concomitant Oral Antidepressant on the Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment Resistant Depression

Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD...

Ibrahim Turkoz , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

Stephane Borentain , MD;

Muideen Adigun , PharmD;

11/22/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products